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Evidence of antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection via
Fc receptor (FcR) was published previously (A. Takeda, C. U. Tuazon, and F. A. Ennis, Science 242:580-583,
1988). To define the entry mechanism of HIV-1 complexed with anti-HIV-1 antibody, we attempted to
determine the receptor molecules responsible for mediating enhancement of HIV-1 infection of monocytic cells.
Monoclonal antibodies to FcRI for immunoglobulin G substantially blocked antibody-dependent enhancement
of HIV-1 infection. Furthermore, we demonstrate a requirement for the CD4 molecule in antibody-enhanced
HIV-1 infection via FcR. Soluble CD4 prevented infection by HIV-1 antibody-treated virus, and enhancement
of infection of virus-antibody complexes was abrogated by a monoclonal antibody to CD4 (anti-Leu3a
antibody). Treatment of human macrophages with an anti-CD4 antibody also inhibited antibody-enhanced
HIV-1 infection of macrophages, supporting our contention that antibody-dependent enhancement of HIV-1
infection via FcR requires CD4 interaction with the virus glycoprotein.
Infection with human immunodeficiency virus type 1
(HIV-1) may induce a humoral immune response that facil-
itates infection rather than protecting the host. Recent
studies have shown the presence of antibodies which en-
hance infection in the sera of HIV-1-infected individuals (10,
20, 25). These antibodies may contribute to the pathogenesis
of the infection, and they are a concern in regard to the
development of HIV vaccines because vaccination may
induce such enhancing antibodies. The antibody-dependent
enhancement of HIV-1 infection is mediated by complement
receptors (20) or by Fc receptors (FcRs) for immunoglobulin
G (IgG), as we demonstrated using an FcR-bearing cell line
(25). The evidence for the latter is as follows. Heat-inacti-
vated sera from HIV-1 antibody-positive individuals or an
IgG fraction from the sera at subneutralizing concentrations
enhanced infection of a monocytic cell line, U937. This
enhancement of infection was blocked by treatment of the
cells with heat-aggregated gamma globulin. The F(ab')2
fraction showed only neutralizing activity, indicating the
requirement of the Fc portion of IgG for the enhancement of
infection. Compatible results were also reported by Jouault
et al. and Matsuda et al., who used radiolabeled HIV-1
envelope protein (11, 16). There are, however, three distinct
classes of FcRs for IgG on human myeloid cells (2). IgG
FcRI (Fc',RI) is the only FcR that binds to monovalent IgG
(human IgGl and IgG3) with high affinity and is expressed on
monocytes and macrophages. FcYRII is a low-affinity recep-
tor for monovalent human IgGl and IgG3 and appears to be
specific for immune complexes. This receptor is expressed
on a wide range of human cells, such as monocytes, macro-
phages, granulocytes, B lymphocytes, and platelets. FcYRIII
also has low affinity for monomeric IgG and is expressed on
macrophages, granulocytes, natural killer cells, and some T
lymphocytes. It is important to identify the relevant class of
FcR to define the entry mechanism of antibody-complexed
HIV-1 into cells. Although it is recognized that HIV-1
* Corresponding author.
infection is initiated by a specific interaction of viral enve-
lope protein with the cell surface receptor CD4 (4, 12), some
glioma cell lines, rhabdomyosarcoma cells, and fibroblasts
appear to be infected with HIV-1 by a CD4-independent
mechanism (3, 8, 26). It is possible that molecules other than
CD4 are responsible for HIV-1 entry, and FcR may also be
a receptor for HIV-1. Therefore, we attempted to determine
the molecules which are responsible for mediating antibody-
dependent enhancement of HIV-1 infection via FcRs. Our
results indicate that antibody-dependent enhancement of
HIV-1 infection proceeds via FcYRI and requires virus
interaction with the CD4 molecule.
MATERIALS AND METHODS
Cells and virus. The human histiocytic lymphoma-derived
cell line U937, which has monocyte characteristics, was
obtained from the American Type Culture Collection, Rock-
ville, Md., and was used for the infection enhancement
assay. The T-lymphoid cell line CEM was used in indicated
experiments. Cells were cultured in RPMI 1640 medium
supplemented with 10% fetal bovine serum (GIBCO, Grand
Island, N.Y.), 10 mM HEPES (N-2-hydroxyethylpiperazine-
N'-2-ethanesulfonic acid) buffer, 2 mM L-glutamine, 100 U
of penicillin per ml, and 100 p.g of streptomycin per ml.
HIV-1, HTLV-IIIB strain, was propagated in H9 cells.
The HTLV-IIIB-infected H9 cells were grown in RPMI 1640
medium supplemented with 20% fetal bovine serum and
antibiotics. Culture supernatants were harvested and titrated
on C8166 cells by a 50% tissue culture infectious dose
(TCID50) assay.
Reagents. A recombinant, soluble form of CD4 protein
(sCD4) (6) was kindly provided by Keith C. Deen (Smith-
Kline and Beecham Laboratories, King of Prussia, Pa.). A
monoclonal antibody (MAb) (anti-Leu3a) without NaN3 was
kindly supplied by Noel Warner (Becton Dickinson, Moun-
tain View, Calif.). MAb 197 (mouse IgG2a) to FcYRI (7) and
MAb IV.3 (mouse IgG2b) to FcYRII (15) were kindly pro-
vided by Michael W. Fanger (Dartmouth Medical School,
Hanover, N.H.). Both MAbs act as ligands for the Fc-
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FIG. 1. Immunofluorescence flow cytometry analysis of Fc,,RI, FcyRIl, Fc,RIII, and CD4 expression in U937 cells with MAbs 32.2, IV.3,
anti-Leulla, and anti-Leu3a, respectively. (A) U937 cells were stained for FcYRI, Fc,RII, and FcYRIII as described in Materials and Methods.
Dotted lines depict negative controls treated with the second antibody alone (for MAbs 32.2 and IV.3) or control mouse IgGl (for MAb
anti-Leulla). (B) U937 cells were stained for dual parameter analysis of FcyRl and CD4.
binding domain. MAb 32.2 (mouse IgGl), which binds to
FcYRI at a site distinct from the ligand-binding site, was also
provided by M. W. Fanger and used for detection of FcYRI
(1). The MAbs anti-Leulla (Becton Dickinson), anti-Leu3a
(Becton Dickinson), and Mo2 (Coulter, Hialeah, Fla.) were
used for staining FcYRIII, CD4, and CD14 (a monocyte/
macrophage phenotype), respectively.
Analysis of surface antigens on cells. Cells (106) in 20 ,ul of
phosphate-buffered saline containing 0.1% NaN3 were
mixed at 4°C for 1 h with 20 [L1 of MAb 32.2 or MAb IV.3 (60
,ug/ml) plus 20 pul of normal human gamma globulin (12
mg/ml; used to block Fc region-specific binding of MAb).
The cells were then washed three times, stained with fluo-
rescein isothiocyanate-conjugated (FITC) goat F(ab')2 anti-
mouse IgG at 4°C for 1 h, washed three times, and analyzed
with a flow cytometer (FACS 440; Becton Dickinson). The
cells were also stained with FITC anti-Leulla, FITC anti-
Leu3a, and FITC Mo2 as described elsewhere. Isotype-
specific control antibodies were run with each sample. For
dual parameter staining of FcRs and CD4, the cells were
stained first with FITC anti-FcR antibodies and then with
phycoerythrin-conjugated anti-Leu3a antibodies.
Preparation of IgG from sera. IgG was fractionated from
HIV-1 antibody-positive sera on a sucrose density gradient,
examined for contamination by radial immunodiffusion
(Cooper Biomedical, Malvern, Pa.), and quantitated by
nephelometry with antibodies to Fc (Beckman, Brea, Calif.).
The purity was also determined by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis.
Infection enhancement assay. The assay was performed as
previously described (25). Briefly, purified IgG from an
HIV-1 antibody-positive serum was serially diluted in phos-
phate-buffered saline at serum dilution equivalents from
10-1 through 10-6, and each of these dilutions (1 ml) was
mixed with an HIV-1 inoculum containing 106 TCID50. The
serum dilution equivalent was based on the original concen-
tration of IgG in the serum. These mixtures were incubated
for 30 min at 4°C and then incubated for 2 h at 37°C with 106
U937 cells. A multiplicity of infection (MOI) of 0.01 was
used unless otherwise stated. After infection, cells were
washed three times and cultured with fresh medium in
25-cm2 plastic flasks (Costar, Cambridge, Mass.). On day 3,
5 ml of the same medium was added, and on day 5, 5 ml of
medium was replaced. Supernatants and cells were har-
vested separately on day 7. Infection of U937 cells was
monitored by assays of the p24 antigen content in culture
supernatants with an HIV-1 capture enzyme-linked immuno-
sorbent assay (Du Pont, Wilmington, Del.) (17) and by
detection of cytoplasmic HIV-1 antigens in U937 cells in an
indirect immunofluorescence microscopy assay; a 1:200 di-
lution of a human serum specimen with antibodies to HIV-1
was used as the first antibody, and a FITC F(ab')2 fragment
of goat antibody to human IgG (Organon Teknika, Cappel,
Malvern, Pa.) was used as the second antibody. As we have
reported previously, the enhancement of infection deter-
mined by p24 production is also characterized by an increase
in the number of HIV-1 antigen-positive cells (25).
Isolation and culture of macrophages. Human monocytes
were isolated by countercurrent centrifugal elutriation of the
mononuclear-cell fraction of peripheral blood cells from
normal donors. Cells in the fraction which contained >85%
monocytes, as judged by cell morphology on Wright-Gi-
emsa-stained cytosmears, were cultured as monolayers of
adherent cells in 48-well plates (Cluster 48; Costar) in
AIM-V medium (GIBCO) supplemented with 1,000 U of
granulocyte-macrophage colony-stimulating factor (Amgen,
Thousand Oaks, Calif.) per ml. On day 11, nonadherent cells
were removed by gentle washing, and monolayers were
pretreated with 5 U of gamma interferon (Collaborative
Research, Bedford, Mass.) for 3 days. At that point, macro-
phages were checked for cell markers by flow cytometry,
and the percentages of cells positive for CD14 (Mo2), FcYRI
(MAb 32.2), FcYRII (MAb IV.3), FcYRIII (anti-Leull), and
CD4 (anti-Leu3a) were 99.3, 99.6, 99.5, 82.1, and 14.6,
respectively. On day 14, they were infected with HIV-1 in
the absence or presence of anti-HIV-1 antibody.
Statistical analysis. Statistical significance was determined
by analysis of variance and the Student-Newman-Keuls
procedure of multiple comparisons.
RESULTS
Effect of MAbs to Fc1,RI and Fc.yRII on infection enhance-
ment in the presence of antibodies to HIV-1. As illustrated in
Fig. 1A, the human monocytic cell line U937 bears two
classes of FcRs, Fc,RI and FcYRII, but does not express
FcYRIII; in this respect it is similar to monocytes (15). To
identify the class of FcR which is responsible for antibody-
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FIG. 2. Effect of MAbs to FcYRI and FcYRII on infection enhancement in the presence of antibodies to HIV-1. U937 cells (106) were
untreated (A) or pretreated with MAb 197 to FcYRI (B) or MAb IV-3 to FcYRII (C) at 5 jLg/ml for 30 min at 4°C and then incubated for 2 h
at 37°C with 104 TCID50 of HIV-1 (MOI, 0.01) or HIV-1 complexed with various concentrations of purified IgG from an HIV-1
antibody-positive serum in the presence of each MAb at 5 ,ug/ml. The MAbs at this concentration saturate the binding sites of FcyRs (7). After
infection, the cells were washed and cultured. Supernatants were harvested on day 7 for determination of p24. Data are presented as the
means + standard deviations of p24 values from duplicate cultures. A repeated experiment showed similar results. The p24 yields from the
culture of the cells which were infected in the presence of IgG antibody to HIV-1 diluted at the serum equivalent of 10-6 were significantly
higher than those in the absence of IgG (P < 0.001) in treatment groups A and C but not in treatment group B.
dependent HIV-1 entry, we used the anti-FcR antibodies
MAb 197 (mouse IgG2a) and MAb IV.3 (mouse IgG2b),
which block FcyRI and FcYRII, respectively (7, 15). HIV-1
infection was significantly enhanced by the presence of IgG
antibody to HIV-1 diluted to the serum equivalent of 10-6 as
compared with the absence of IgG (P < 0.001) when cells
were untreated or treated with MAb IV.3, but infection was
not enhanced when cells were treated with MAb 197 (Fig. 2).
Thus, treatment of U937 cells with MAb 197 to block FcYRI
inhibited enhancement of infection in the presence of HIV-1
antibodies, whereas MAb IV.3, a ligand for FcyRII, did not
block enhancement.
Effect of sCD4 on enhancement of HIV-1 infection in the
presence of antibodies to HIV-1. The CD4 molecule has been
identified as a crucial component of the cell surface receptor
for HIV-1 (4, 12). All populations of U937 cells were found
to express CD4 molecules (Fig. 1B). It was thus impossible
to separate a CD4-negative cell population. To address the
question of whether the infection pathway via FcR is inde-
pendent of CD4, we used a recombinant soluble form of the
CD4 molecule (sCD4). We first tested the capacity of sCD4
to block infection of U937 cells with HIV-1 (Fig. 3A). The
results showed that the sCD4 preparation blocked the infec-
tivity of HIV-1 for U937 cells. Three hundred nanograms of
sCD4 was required to block the infectivity of an HIV-1
inoculum which possessed 104 TCID50. On the basis of these
results, we examined the effect of sCD4 on enhancement of
HIV-1 infection in the presence of antibodies to HIV-1 (Fig.
3B). HIV-1 infection was significantly enhanced by the
presence of IgG antibody to HIV-1 diluted at serum equiv-
alents of 10-4-5 and 10' as compared with the absence of
IgG (P < 0.001). In contrast to the enhancement of infection
found in the absence of sCD4, preincubation with 1,500 ng of
sCD4 completely inhibited infection not only by HIV-1 but
also by HIV-1 complexed with antibodies. In this experi-
ment, neither nonspecific inhibition of cell growth nor toxic
effects of sCD4 were observed in the cultures. When U937
cells were treated with 300 ng of sCD4, a low level of
infection was detectable at the 10' dilution of IgG antibod-
ies, the optimal dilution of serum for demonstrating enhance-
ment. The results of another experiment we performed also
indicated that antibody-dependent enhancement of infection
is completely blocked by a sufficient quantity of sCD4,
regardless of whether antibodies are added before or after
treatment with sCD4 (data not shown).
Effect of anti-CD4 antibody on infection enhancement in the
presence of antibodies to HIV-1. In parallel experiments, we
examined whether a monoclonal antibody to the CD4 anti-
gen would block infection enhancement of monocytic cells
(Table 1). The antibody we used was anti-Leu3a antibody
because the recognition site on CD4 for gpl20 is close to the
Leu3a antigen epitope (21) and because this antibody has a
murine IgGl subclass that cannot be a ligand for FcR by
itself (2). U937 cells were pretreated with anti-Leu3a anti-
body or an irrelevant murine IgGl antibody at 5 jig/ml for 30
min at room temperature and then incubated for 2 h at 37°C
with 105 TCID50 of HIV-1 (MOI, 0.1) or HIV-1 complexed
with various concentrations of IgG from an HIV-1 antibody-
positive serum. These samples were further cultured in the
continuous presence of each antibody at 5 ,ug/ml, and the
supernatants and cells were harvested on day 7. HIV-1
infection of U937 cells was significantly enhanced by IgG
antibody to HIV-1 diluted at serum equivalents of 10-3 and
10-4 as compared with the control, which was infected with
HIV-1 alone, when cells were cultured in either the absence
or the presence of an irrelevant murine IgGl antibody (P <
0.05). In contrast, the presence of anti-Leu3a antibody in the
cultures abrogated the enhancement of infection; essentially
no cells that were positive for HIV-1 cytoplasmic antigens
were detected in these cultures (less than 0.1%). The virus
titers contained in samples for cells exposed to HIV-1 alone
and HIV-1 complexed with IgG at the 10-3 dilution were 40
Control
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FIG. 3. Inhibition of infectivity of HIV-1 for U937 cells by sCD4.
An HIV-1 inoculum containing 104 TCID50 was preincubated with
various concentrations of sCD4 for 30 min at 37°C and then
incubated for 2 h at 37°C with 106 U937 cells. The infected cells were
then washed and cultured with fresh media. The supernatants and
cells were harvested separately on day 7. Each plot represents the
means of duplicate samples. The p24 values from cultures not
treated with sCD4 were calculated as 100% of virus yield. The cells
which were exposed to the inoculum with 300 ng or more of sCD4
were negative for cytoplasmic HIV-1 antigens. (B) Effect of sCD4
on enhancement of HIV-1 infection in the presence of antibodies to
HIV-1. The IgG from an HIV-1 antibody-positive serum was serially
diluted and mixed with an HIV-1 inoculum containing 104 TCID50.
These mixtures were untreated or treated with 300 or 1,500 ng of
sCD4 for 30 min at 37°C and then incubated for 2 h at 37°C with 106
U937 cells (MOI, 0.01). After infection, the cells were washed and
cultured. The supematants were harvested on day 7. Data represent
the means ± standard deviations of two values. The p24 concentra-
tions from cultures treated with 1,500 ng of sCD4 were undetectable
(<0.001 ng/ml), and the cells from these cultures were negative for
cytoplasmic HIV-1 antigen by indirect immunofluorescence.
and 160 TCID50 of HIV-1, respectively, whereas the titers in
all samples from cells treated with anti-Leu3a were less than
4 TCID50.
The results showed that treatment with anti-Leu3a anti-
body substantially reduced the level of virus yields from
U937 cells as well as CEM cells that were exposed to HIV-1,
indicating that infection of U937 cells with HIV-1 or anti-
body-complexed HIV-1 also requires interactions between
HIV-1 and CD4 molecules. Moreover, anti-Leu3a antibody
abrogated enhancement of infection with HIV-1 in the pres-
ence of antibodies to HIV-1, which indicated that cellular
CD4 molecules are necessary for infection enhancement.
Infection enhancement in cultured macrophages and the
effect of anti-CD4 antibody. To supplement our conclusions
concerning a requirement for CD4 in FcR-mediated entry,
we performed experiments with cultured human macro-
phages (Fig. 4). HIV-1 infection was significantly enhanced
at subneutralizing concentrations of an IgG antibody to
HIV-1, e.g., at a serum equivalent of 10-6 (P < 0.001). In
contrast, treatment of cultured macrophages with anti-Leu3a
antibody inhibited enhancement of HIV-1 infection, support-
ing the results obtained in U937 cells.
DISCUSSION
This report shows convincing evidence that HIV-1 inter-
action with CD4 is required for infection by HIV-1 antibody
complexes. First, antibody-dependent enhancement of
HIV-1 infection was completely blocked by a sufficient
quantity of sCD4. It may be asked whether effect of sCD4
may be due to nonspecific blocking of the binding of virus-
antibody complexes to FcR by sCD4 on the basis of homol-
ogy between CD4 and the Fc portion of IgG as part of the
immunoglobulin gene superfamily. However, this possibility
was ruled out because we found that sCD4 did not inhibit
FcR-mediated infection enhancement in the dengue virus
system (data not shown). Second, treatment of the target
cells with anti-CD4 antibody abrogated enhancement of
infection by HIV-1 in the presence of antibodies to HIV-1.
This finding concurs with the results of our experiments with
sCD4 and argues against the possibility that sCD4 blocks
infection enhancement by inducing conformational changes
of other sites, such as the fusion site on HIV-1 gp160.
Additional experiments which we performed with cultured
human -macrophages, which possess FcYRI, FcYRII, and
Fc,RIII, supplemented our conclusion concerning the re-
quirement for CD4 in the entry of HIV-1 antibody com-
plexes.
The studies reported here demonstrate that Fc RI, a
high-affinity FcR for IgG, is involved in antibody-dependent
enhancement of HIV-1 infection. We have previously pre-
sented evidence that FcRs mediate enhanced entry of anti-
body-complexed HIV-1, using a monocytic cell line, U937
(25). We now report that a MAb to FcYRI blocked enhance-
ment of HIV-1 infection. Because of its high affinity (Ka =
108 to 109 M-1) for IgG (2), FcYRI may well attract antibody-
complexed HIV-1 virions more efficiently than other FcYlRs
do. The results of our experiments, however, do not exclude
a possible role of FcYRII and FcyRIII in the enhancement of
HIV-1 infection. Although treatment with MAb to FcYRII
failed to block enhancement of infection, it is conceivable
that binding of the monomeric ligand antibody IV.3 to
Fc,RII may be overwhelmed by antibody-virus complexes
which are potent ligands for Fc RII. Distinct from FcyRI,
which attracts monomeric IgG, Fc,,RII has low affinity for
the monomeric ligand (2), and thus blocking of FcYRII by
MAb IV.3 may not be as stable as blocking of FcYRI by MAb
197. There is some evidence from studies with flaviviruses
that both a trypsin-sensitive FcYR for IgG2a and a trypsin-
resistant FcYR for IgG2b, or FcYRI and FcYRII, can contrib-
ute to the phenomenon of infection enhancement (13, 14,
23). In this respect, we are currently conducting a more
precise study to determine the role of Fc RII in the enhance-
ment of HIV-1 infection by employing heterocross-linked
antibodies made by antibodies which are directed against
envelope proteins of HIV-1 and against FcYRII. We are also
creating a cell line for the same objective which will express
FcYRII as well as CD4, but not FcYRI or FcYRII, by
transfection of the CD4 gene into FcYRII-bearing cell lines.
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TABLE 1. Effect of anti-CD4 antibody on infection enhancement in the presence of antibodies to HIV-1
IgG concn (serum p24 concn (ng/ml)a with:
Cell line dilution Normal mouse Anti-
equivalent) No treatment IgGIb Leu3ab
U937 OC 39.6 ± 2.3 (1.0) 26.0 ± 0.4 (1.0) 2.5 ± 0.1
lo-1 1.1 ± 0.1 (0.03) 2.5 ± 0.1 (0.06) 1.4 ± 0.0
10-2 35.6 + 0.1 (0.90) 22.1 ± 0.8 (0.85) 2.6 ± 0.2
1o-3 79.1 ± 1.0 (2.00) 41.2 ± 0.2 (1.58) 2.6 ± 0.1
10-4 58.8 ± 2.3 (1.48) 40.0 ± 0.6 (1.54) 2.4 ± 0.1
10-5 NDd ND 2.5 ± 0.0
10-6 41.7 ± 1.1 (1.05) 32.6 ± 1.2 (1.25) 2.6 ± 0.1
CEM OC 36.3 ± 0.5 24.4 ± 0.1 2.5 ± 0.1
a Results are expressed as the means + standard deviations of duplicate cultures. The numbers in parentheses show the enhancement indices relative to the
infection with HIV-1 alone.
b Anti-Leu3a (subclass IgGl) and irrelevant (normal mouse) IgGl were used at concentrations of 5 ,ug/ml.
c HIV alone.
d ND, Not deter'mined.
Recently, results compatible with ours were presented by
Perno et al. who reported that enhanced infection of HIV-1
in fresh and cultured human monocytes/macrophages was
blocked by inhibitors of gpl20-CD4 binding, that is, sCD4
and OKT4A (19). On the other hand, there is a report which
contrasts with our results. Homsy et al. have reported that in
the presence of antibodies to HIV-1, FcYRIII mediates
HIV-1 infection of cultured macrophages which possess
Fc RI, Fc RII, and Fc,RIII, and that this antibody-en-
hanced infection is not associated with CD4 (9). In that
study, neither an antibody to Fc RI nor an antibody to
FcSRII blocked enhancement. An antibody to CD4
(OKT4A) also did not prevent enhancement of HIV-1 infec-
tion, although inhibition by sCD4 was ambiguous. It is
possible that the cells, the MAbs used for blocking, or the
sera studied may be responsible for these differences. Stud-
ies with MAbs are complicated by the possibility that the
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FIG. 4. Infection enhancement in cultured macrophages and the
effect of anti-CD4 antibody. Adherent macrophages (5 x 105) were
treated with anti-Leu3a antibody at 5 ji.g/ml (0) or left untreated (0)
for 30 min at room temperature and then incubated for 2 h at 370C
with Sx 104 TCID50 of HIV-1 (MOI, 0.1) or HIV-1 complexed with
various concentrations of IgG from an HIV-1 antibody-positive
serum in the absence or presence of ariti-Leu3a antibody. The
infected macrophages were gently washed three times and cultured
with the same medium. Supernatants were harvested on day 6 for
determination of p24. Each plot represents the means ± standard
deviations of duplicate cultures.
antibodies may nonspecifically alter viral infection through
steric hindrance of other receptor molecules. Experiments
using cells transfected with a gene for a single class of FcRs
and for CD4 might further resolve this question.
With respect to our conclusion of the requirement for
CD4, it is not certain at which stage of the entry process of
the antibody-complexed virus the interaction between
HIV-1 and CD4 molecules occurs. The binding of the
virus-antibody complexes to FcYRI might facilitate viral
entry by potentiating virus interaction with CD4 receptors
on the cell surface or on the membrane of endosomes.
Although the ordinary pathway of HIV-1 infection is still
controversial, CD4 receptor-mediated endocytosis appears
to be the mode of free virus infection (18) in addition to
CD4-dependent entry via direct fusion between the viral and
plasma membranes (24). The internalization of HIV-1 into
endosomes may be promoted by FcR-mediated endocytosis
of antibody-virus complexes, and after internalization HIV-1
may penetrate into the cytosol via intracellular fusion with
the endosomal membrane as a result of binding with CD)4
receptors on the endosomal membranes.
Our results provide an intriguing suggestion about the role
of virus receptors in the antibody-dependent enhancement of
infection by other viruses, in which antibody-mediated at-
tachment of virus to the cell via FcRs has been considered to
be sufficient to establish infection without participation of
virus receptors (5, 22). Identification of the specific virus
receptor molecules should allow a more precise understand-
ing of the structural basis for the mechanism of infection
enhancement in other virus systems. The ability of sCD4 to
block infection enhancement in vitro may have important
implications for preventing or reducing the development of
HIV-1 infection which may be mediated by antibodies in
patients infected with HIV-1.
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